Lirilumab
Showing 1 - 12 of 12
Bladder Cancer Trial in United States (Nivolumab, Nivolumab/Lirilumab)
Completed
- Bladder Cancer
-
Tampa, Florida
- +7 more
Nov 4, 2022
Advanced Cancer Trial in Kashiwa-shi, Kobe-shi (Lirilumab, Nivolumab, Ipilimumab)
Completed
- Advanced Cancer
- Lirilumab
- +2 more
-
Kashiwa-shi, Chiba, Japan
- +1 more
Mar 9, 2022
CANCER,NOS Trial in Worldwide (Lirilumab, Nivolumab, Ipilimumab)
Completed
- CANCER,NOS
- Lirilumab
- +2 more
-
San Francisco, California
- +29 more
Dec 10, 2020
Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia Trial in Houston (Lirilumab, Rituximab)
Completed
- Leukemia
- +2 more
- Lirilumab
- Rituximab
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 26, 2020
Leukemia Trial in Houston (Lirilumab, Nivolumab, Azacitidine)
Terminated
- Leukemia
- Lirilumab
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 6, 2020
Children, Adolescents and Young Adults With Refractory or Recurrent Malignancies Trial in Worldwide (Ribociclib, Topotecan,
Unknown status
- Children, Adolescents and Young Adults With Refractory or Recurrent Malignancies
- Ribociclib
- +9 more
-
Copenhagen, Denmark
- +6 more
Feb 23, 2021
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid
Terminated
- Acute Biphenotypic Leukemia
- +3 more
- Azacitidine
- Lirilumab
-
Houston, TexasM D Anderson Cancer Center
Sep 5, 2019
Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Toripalimab+cetuximab)
Recruiting
- Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
-
Shanghai, Shanghai, Chinathe Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Nov 1, 2022
Acute Myeloid Leukemia Trial in France (IPH2102 at 0.1 mg/kg, IPH2102 at 1 mg/kg, Placebo (normal saline solution))
Completed
- Acute Myeloid Leukemia
- IPH2102 at 0.1 mg/kg
- +2 more
-
Amiens, France
- +42 more
Sep 6, 2018